Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. (December 2016)

• Record Type: Journal Article
• Authors: Yamagiwa, Yoko; Asano, Mai; Kawasaki, Youhei; Korenaga, Masaaki; Murata, Kazumoto; Kanto, Tatsuya; Mizokami, Masashi; Masaki, Naohiko
• Is Part Of: Cytokine. Volume 88(2016)
• Page Start: 29
• Page End: 36
• Publication Date: 2016-12
• Subjects: Chronic hepatitis C -- IL28B -- IP-10 -- Rapid virologic response -- Telaprevir; ALT alanine aminotransferase -- AST aspartate aminotransferase -- CHC chronic hepatitis C -- CI confidential interval -- DAA direct-acting antivirals -- ETR end of treatment virologic response -- EVR early virologic response -- FIB-4 fibrosis-4 -- GGT gamma-glutamyl transpeptidase -- GWAS genome-wide association studies -- HCV hepatitis C virus -- IL28B interleukin-28B -- IP-10 interferon-gamma-inducible protein-10 -- ISG interferon-stimulated gene -- OR odds ratio -- Peg-IFN pegylated-interferon-alpha -- RBV ribavirin -- ROC receiver operating characteristic -- RVR rapid virologic response -- SVR sustained virologic response -- TVR telaprevir -- WBC white blood cell; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2016.07.004
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: IL28B genotype still affected response to TVR-based therapy. Serum IP-10 levels were significantly lower in patients who achieved RVR. Measurement of serum IP-10 is more important in patients with IL28B non-TT genotype. Abstract: Aim: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B ( IL28B ) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy. We aimed to investigate the usefulness of pretreatment serum IP-10 levels and IL28B genotyping in predicting sustained virologic response (SVR) to TVR-based triple therapy. Methods: In this multi-center study, patients infected with hepatitis C virus genotype 1 with high viral load (⩾5.0 log IU/mL) were treated with TVR for 12 weeks and Peg-IFN/RBV for 24 weeks in Japan. IL28B genotype, serum IP-10 levels, other clinical parameters, and drug dosages were assessed before treatment. Results: We included 121 patients who were treated with TVR for at least 8 weeks and Peg-IFN/RBV for 24 weeks. The median IP-10 levels were significantly lower in rapid virologic response (RVR) or SVR in the IL28B non-TT genotype group, with no significant difference in the TT genotype group. RVR rates were significantly lower in the group with higher serum IP-10 levels (>450 pg/mL). In the non-TT IL28B genotype group, RVR and SVR rates were significantly lower in the group with higher IP-10 levels. SVR rates in the group with lower IP-10 levels (<450 pg/mL) increased to 82% for those showing RVR, but reduced to 27% in the group with higher IP-10 levels for those not showing RVR. Conclusions: Determination of serum IP-10 levels before treatment could be useful for predicting favorable virologic response to TVR-based triple therapy, especially in patients with IL28B non-TT genotype.